Get started
Author

Hwankyu Kang

Observed name: H.J. Kang
OpenAlex ID: A5010271373
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis
2013 · Kevin Pethe, Pablo Bifani, et al. · Nature Medicine · 608
Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent
2014 · Sunhee Kang, Ryang Yeo Kim, et al. · Journal of Medicinal Chemistry · 179
Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects
2021 · Jeongjun Kim, Jinho Choi, et al. · Antimicrobial Agents and Chemotherapy · 39
A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment
2022 · Yeejin Jeon, Hwankyu Kang, et al. · Cancers · 22
PDF
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial
2022 · Jeongjun Kim, Jinho Choi, et al. · Antimicrobial Agents and Chemotherapy · 16
Discovery of 4H-chromeno[2,3-d]pyrimidin-4-one derivatives as senescence inducers and their senescence-associated antiproliferative activities on cancer cells using advanced phenotypic assay
2020 · Sangmi Oh, Ji Young Lee, et al. · European Journal of Medicinal Chemistry · 10
PDF
Abstract 2255: Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors
2023 · Bae Jung Choi, Devalingam Devalingam, et al. · Cancer Research · 4
Abstract 4139: Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy
2019 · Yeong-In Yang, Hwankyu Kang, et al. · Cancer Research · 4
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
2021 · Angela Tatiana Alistar, Anthony B. El-Khoueiry, et al. · Journal of Clinical Oncology · 2
Abstract 4974: Q702, selective Axl/Mer/CSF1R triple kinase inhibitor enhance the activity of immune checkpoint inhibitor by alteration of immunosuppressive tumor microenvironment
2020 · Yeong-In Yang, Hwankyu Kang, et al. · Cancer Research · 2
Abstract 4139: Q702, selective Axl, Mer and CSF1R triple kinase inhibitor with dual potentials leading to tumor regression: Immuno-oncology therapy and targeted cancer therapy
2019 · Yeong-In Yang, Hwankyu Kang, et al. · Immunology · 1
Abstract A009: Preclinical safety and efficacy QP101: A novel HER2-targeting dual payload ADC combining topoisomerase I (TOP1) and cyclin dependent kinase 7 (CDK7) inhibitors
2026 · Kiyean Nam, Hwankyu Kang, et al. · Clinical Cancer Research
Abstract A052: Enhancing potency through synergy: QP101, a novel HER2 targeting dual payload ADC shows potent preclinical activities
2025 · Yeong-In Yang, Hwankyu Kang, et al. · Molecular Cancer Therapeutics
645 A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors
2023 · Seung-Tae Kim, Hong Jae Chon, et al. · Journal for ImmunoTherapy of Cancer
PDF
651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors
2023 · Devalingam Mahalingam, Angela Alistar, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract A205: Q701, a selective Axl and Mer inhibitor as an immune checkpoint inhibitor
2018 · Yeong-In Yang, Hwankyu Kang, et al. · Molecular Cancer Therapeutics
Abstract B162: Highly selective, orally available CDK7 inhibitor for cancer therapy
2018 · Yeejin Jeon, Donghoon Yu, et al. · Molecular Cancer Therapeutics
Combined Effect of Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and Programmed Cell Death 1 Ligand 1 (PD-L1) expression in tumor infiltrating lymphocytes on prognostic outcomes after resection of hepatocellular carcinoma
2017 · J. An, H.J. Kang, et al. · Journal of Hepatology
Development of novel vaccine candidates for Mycobacterium tuberculosis involved in Phagosome Maturation Arrest (PMA)
2013 · Sei Jin Park, Jichan Jang, et al. · 한국실험동물학회 학술발표대회 논문집
Works count: 19
Citation count: 887
H-index: 6
I10-index: 6
Year
Topic
Type